Wall Street analyst estimates for Belite Bio, Inc (BLTE): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily.
Consensus price target
$245.83 (+62 % vs price $152.17)
between $206.00 and $303.00 · 7 targets published in the last quarter
Closing price, Nov 3
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $22.5M | $10.9M – $44.3M | -$3.18 | 7 |
| 2027E | $274M | $151M – $397M | $1.90 | 6 |
| 2028E | $543M | $310M – $1.1B | $6.17 | 5 |
Figures in USD · consensus as of November 2, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 6 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 6 |
| Avg rating (−2 sell to +2 buy) | 1.00 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-09 | $-0.79 | ||
| 2026-08-12 | $-0.70 | $-0.73 | +4.1% |
| 2026-05-20 | $-0.34 | $-0.60 | +43.3% |
| 2026-03-02 | $-0.38 | $-0.56 | +32.1% |
| 2025-11-10 | $-0.65 | $-0.53 | -22.6% |
| 2025-08-11 | $-0.50 | $-0.47 | -6.4% |
| 2025-05-13 | $-0.45 | $-0.36 | -25.0% |
| 2025-03-17 | $-0.32 | $-0.30 | -6.7% |
Valuation Ratios
| Price / Book | 7.93 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 |
| Research & Development | $3.7M | $7.4M | $8.9M | $24.8M | $29.9M | $45.4M |
| Selling, General & Admin | $2.1M | $2.4M | $4.0M | $6.8M | $10.1M | $38.8M |
| Operating Expenses | $5.7M | $9.8M | $12.8M | $31.7M | $40.0M | $84.2M |
| Operating Income | -$5.7M | -$9.8M | -$12.8M | -$31.7M | -$40.0M | -$84.2M |
| EBITDA | -$5.7M | -$9.6M | -$12.4M | -$31.2M | -$35.7M | -$77.1M |
| Interest Expense | $21,000 | 0 | $16,000 | $25,000 | $20,000 | 0 |
| Pre-tax Income | -$5.8M | -$9.7M | -$12.6M | -$31.6M | -$36.1M | -$77.6M |
| Income Tax | $1,000 | 0 | 0 | $9,000 | $6,000 | 0 |
| Net Income | -$5.8M | -$9.7M | -$12.6M | -$31.6M | -$36.1M | -$77.6M |
| EPS | -$0.62 | -$0.40 | -$0.63 | -$1.19 | -$1.18 | -$2.31 |
| EPS (Diluted) | -$0.62 | -$0.40 | -$0.63 | -$1.19 | -$1.18 | -$2.31 |
| Shares Outstanding (Diluted) | 9.2 M | 24.1 M | 20.0 M | 26.6 M | 30.5 M | 33.5 M |
Price
| Price | $152.17 (closing price, November 3, 2026) |
| Market Cap | $6.1B |
| Exchange | NASDAQ |
| Country | US |
Related companies: KOD · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L
Explore sector: Healthcare · Biotechnology
More sections of BLTE: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks